In Silico Study Supports the Efficacy of a Reduced Dose Regimen for Stavudine

Overview

Journal Antiviral Res

Publisher Elsevier

Date 2011 Aug 31

PMID 21875620

Citations 5

Authors

Selwyn J Hurwitz

Raymond F Schinazi

Affiliations

Soon will be listed here.

Abstract

Stavudine (d4T) is used extensively as part of HAART in resource poor settings, despite its toxicities. The revised WHO guidelines specify replacement of d4T with less toxic but more expensive drugs when feasible, and that d4T doses be standardized to 30 mg twice daily (bid) (irrespective of body-weight), from the approved 40 mg bid in adults (body-weight ≥60 kg). Therefore, an in silico population pharmacokinetic and biochemical model was utilized to compare relative efficacies of the two doses in humans. Assessment of predicted quartile ranges of simulated concentrations of the triphosphate of d4T suggested sufficient trough concentrations to inhibit wild type HIV-1 reverse transcriptase at the reduced dose, lending support to the revised WHO recommendations.

Citing Articles

Why Certain Repurposed Drugs Are Unlikely to Be Effective Antivirals to Treat SARS-CoV-2 Infections.

Hurwitz S, De R, LeCher J, Downs-Bowen J, Goh S, Zandi K Viruses. 2024; 16(4).

PMID: 38675992 PMC: 11053489. DOI: 10.3390/v16040651.

Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model.

Sy S, Malmberg R, Matsushima A, Asin-Prieto E, Rosenkranz B, Cotton M Int J Antimicrob Agents. 2015; 45(4):413-9.

PMID: 25697412 PMC: 4746231. DOI: 10.1016/j.ijantimicag.2014.12.016.

Estimation of intracellular concentration of stavudine triphosphate in HIV-infected children given a reduced dose of 0.5 milligrams per kilogram twice daily.

Sy S, Innes S, Derendorf H, Cotton M, Rosenkranz B Antimicrob Agents Chemother. 2013; 58(2):1084-91.

PMID: 24295968 PMC: 3910857. DOI: 10.1128/AAC.01717-13.

Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa.

Brennan A, Maskew M, Ive P, Shearer K, Long L, Sanne I J Int AIDS Soc. 2013; 16:18794.

PMID: 24256692 PMC: 3835788. DOI: 10.7448/IAS.16.1.18794.

Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors.

Hurwitz S, Schinazi R Drug Discov Today Technol. 2013; 9(3):e183-e193.

PMID: 23554824 PMC: 3612025. DOI: 10.1016/j.ddtec.2012.09.003.

References

Hurwitz S, Asif G, Schinazi R . Development of a population simulation model for HIV monotherapy virological outcomes using lamivudine. Antivir Chem Chemother. 2008; 18(6):329-41. DOI: 10.1177/095632020701800605. View

Becher F, Landman R, Mboup S, Kane C, Canestri A, Liegeois F . Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients. AIDS. 2004; 18(2):181-7. DOI: 10.1097/00002030-200401230-00006. View

Diamond T, Roshal M, Jamburuthugoda V, Reynolds H, Merriam A, Lee K . Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. J Biol Chem. 2004; 279(49):51545-53. PMC: 1351161. DOI: 10.1074/jbc.M408573200. View

Dube M, Komarow L, Mulligan K, Grinspoon S, Parker R, Robbins G . Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr. 2007; 45(5):508-14. DOI: 10.1097/QAI.0b013e3181142d26. View

Pedrol E, Martin T, del Pozo M, Flores J, Sanz J, Carton J . [Efficacy and safety of a reduced-dose of stavudine in HIV-infected patients under immunological and virological stable conditions]. Med Clin (Barc). 2007; 129(10):361-5. DOI: 10.1157/13110209. View

Parikh U, Bacheler L, Koontz D, Mellors J . The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol. 2006; 80(10):4971-7. PMC: 1472090. DOI: 10.1128/JVI.80.10.4971-4977.2006. View

Gallant J, Staszewski S, Pozniak A, DeJesus E, Suleiman J, Miller M . Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004; 292(2):191-201. DOI: 10.1001/jama.292.2.191. View

Pujari S, Dravid A, Naik E, Bhagat S, Tash K, Nadler J . Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr. 2005; 39(2):199-202. View

Bygrave H, Ford N, Van Cutsem G, Hilderbrand K, Jouquet G, Goemaere E . Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years. J Acquir Immune Defic Syndr. 2010; 56(3):e75-8. DOI: 10.1097/QAI.0b013e3182097505. View

10.

van Griensven J, Zachariah R, Rasschaert F, Mugabo J, Atte E, Reid T . Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda. Trans R Soc Trop Med Hyg. 2009; 104(2):148-53. DOI: 10.1016/j.trstmh.2009.07.009. View

11.

Hernandez-Santiago B, Obikhod A, Fromentin E, Hurwitz S, Schinazi R . Short communication cellular pharmacology of 9-(beta-D-1,3-dioxolan-4-yl) guanine and its lack of drug interactions with zidovudine in primary human lymphocytes. Antivir Chem Chemother. 2008; 18(6):343-6. DOI: 10.1177/095632020701800606. View

12.

Ait-Mohand H, Bonmarchand M, Guiguet M, Slama L, Marguet F, Behin A . Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot study. HIV Med. 2008; 9(9):738-46. DOI: 10.1111/j.1468-1293.2008.00616.x. View

13.

Schinazi R, Hernandez-Santiago B, Hurwitz S . Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses. Antiviral Res. 2006; 71(2-3):322-34. PMC: 7685422. DOI: 10.1016/j.antiviral.2006.03.012. View

14.

Horton C, Dudley M, Kaul S, Mayer K, Squires K, Dunkle L . Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex. Antimicrob Agents Chemother. 1995; 39(10):2309-15. PMC: 162934. DOI: 10.1128/AAC.39.10.2309. View

15.

Balimane , Sinko . Involvement of multiple transporters in the oral absorption of nucleoside analogues. Adv Drug Deliv Rev. 2000; 39(1-3):183-209. DOI: 10.1016/s0169-409x(99)00026-5. View

16.

Sanchez-Conde M, de Mendoza C, Jimenez-Nacher I, Barreiro P, Gonzalez-Lahoz J, Soriano V . Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity. HIV Clin Trials. 2005; 6(4):197-202. DOI: 10.1310/ed57-eu48-rk6a-e5u0. View

17.

Hurwitz S, Asif G, Kivel N, Schinazi R . Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation model. Antimicrob Agents Chemother. 2008; 52(12):4241-50. PMC: 2592851. DOI: 10.1128/AAC.00054-08. View

18.

Hellerstein M, Hanley M, Cesar D, Siler S, Papageorgopoulos C, Wieder E . Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med. 1999; 5(1):83-9. DOI: 10.1038/4772. View

19.

Zhu Z, Ho H, Hitchcock M, Sommadossi J . Cellular pharmacology of 2',3'-didehydro-2',3'-dideoxythymidine (D4T) in human peripheral blood mononuclear cells. Biochem Pharmacol. 1990; 39(9):R15-9. DOI: 10.1016/0006-2952(90)90418-k. View

20.

Walensky R, Wood R, Ciaranello A, Paltiel A, Lorenzana S, Anglaret X . Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis. PLoS Med. 2011; 7(12):e1000382. PMC: 3014084. DOI: 10.1371/journal.pmed.1000382. View